23andMe, startup cell therapy company line up SPAC mergers as another young biotech eyes IPO

A consumer genetics company working with a Big Pharma player on therapeutics, a cutting-edge Stanford spinout focused on making stem cell transplants more efficient and effective and a childhood cancer drug startup hope to be the 10th, 11th and 12th Bay Area life sciences companies to go public...

Click to view original post